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ABSTRACT
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most frequent malignant neoplasms 
among Caucasian patients. Despite the fact that they seldom metastasise and are not directly fatal, they constitute 
a significant clinical issue. Such cancers infiltrate surrounding tissues and destroy the surrounding structures, e.g. 
bones and cartilages, as a result of which such structures develop into severe aesthetic defects and significantly 
deteriorate the life quality of the patients. Among patients from the high-risk group (namely patients under chronic 
immunosuppression or those genetically predisposed to develop UV-induced skin cancers) skin cancers may be ag-
gressive and fatal. The Oncology Department of the Polish Dermatology Society (Polish: Sekcja Onkologiczna Polsk-
iego Towarzystwa Dermatologicznego — PTD) and the Melanoma Academy Department of the Polish Society of On-
cological Surgery (Polish: Sekcja Akademia Czerniaka Polskiego Towarzystwa Chirurgii Onkologicznej — PTChO), 
based on the current European guidelines, American recommendations of the National Comprehensive Cancer 
Network (revision 1.2015), and interventional reviews of publications elaborated by the Cochrane Skin Group, 
attempted to systemise the diagnostic and therapeutic procedures and determine homogenous rules of primary 
and secondary prevention in patients suspected/diagnosed with a basal cell or squamous cell carcinoma. This 
paper presents actual recommendations regarding skin cancer diagnosis and treatment, taking all related benefits 
and challenges into consideration, as well as recommendations for post-treatment patient monitoring.
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Introduction
Basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC) are the most frequent malignant 
neoplasms among Caucasian patients. Despite the fact 
that they seldom metastasise and are not directly fatal, 
they constitute a significant clinical issue. Such cancers 
infiltrate surrounding tissues and destroy the surround-
ing structures, e.g. bones and cartilages, as a result of 
which such structures develop into severe aesthetic 
defects and significantly deteriorate the life quality of 
the patients. Among patients from the high-risk group 
(namely patients under chronic immunosuppression or 
those genetically predisposed to develop UV-induced 
skin cancers) skin cancers may be aggressive and fatal. It 
should also be underlined that melanomas are more fre-
quent among patients who have previously suffered from 
a skin cancer, compared to the general population [1].
The Oncology Department of the Polish Dermato-
logy Society (Polish: Sekcja Onkologiczna Polskiego 
Towarzystwa Dermatologicznego — PTD) and the 
Melanoma Academy Department of the Polish Soci-
ety of Oncological Surgery (Polish: Sekcja Akademia 
Czerniaka Polskiego Towarzystwa Chirurgii Onko-
logicznej — PTChO), based on the current European 
guidelines, American recommendations of the National 
Comprehensive Cancer Network (revision 1.2015), and 
interventional reviews of publications elaborated by 
the Cochrane Skin Group, attempted to systemise the 
diagnostic and therapeutic procedures and determine 
homogenous rules of primary and secondary prevention 
in patients suspected/diagnosed with a basal cell or squa-
mous cell carcinoma. It should be underlined that this 
paper will not cover the issue of pre-malignant condi-
tions (e.g. actinic keratosis) or squamous cell carcinomas 
situated in the genital area, nail beds, or in the mouth.
Epidemiology
Skin cancers make up 75% of all diagnosed malig-
nancies [2]. The risk of developing this type of tumour 
throughout life (in Caucasian patients) exceeds 20%. 
The cancer incidence rate grows with increasing age 
(most cases are diagnosed in people in their eighties). In 
2011, a total of 11,439 new cases (5408 in male patients 
and 6031 in female patients) were noted in Poland, trans-
lating into morbidity of 7.5% and 8.3%, respectively [2, 
3]. Unfortunately, a significant underestimation should 
be expected due to faulty reporting to the National 
Register of Cancers.
Basal cell carcinoma is definitely the most common 
skin cancer, constituting approximately 80% of all skin 
cancers. Squamous cell carcinoma holds the second posi-
tion, constituting approximately 15–20% of skin cancers 
[2]. Other forms are significantly more seldom [4].
Risk factors
Rapidly increasing BCC and SCC morbidity is 
caused mostly by excessive exposure to UV light. The 
main reasons of increasing frequency of skin cancers are 
usually related to changes in lifestyle including dress-
ing style, “fashionable” suntan, migration of people 
with first, second, and third skin phototype to regions 
with extensive solar exposure, permanent stays in the 
mountains or low latitude, and using UV-emitting lamps 
(solariums). An important risk factor of BCC and SCC 
comprises also the occupational exposure to UV light 
among people working outside without using any photo-
protection [5]. Table 1 presents skin cancer risk factors.
Diagnostics
Primary diagnosis is determined based on the his-
tory and clinical image typical for BCC and SCC. 80% 
of skin cancers are located on the head and neck, while 
the remaining 20% are located on the extremities and 
torso [3, 5]. It should be underlined that melanoma risk 
is also higher in the latter group.
Skin cancers often develop in several lesions. This 
concerns in particular patients in their seventies with 
severe skin photodamage. Quite often such patients 
are diagnosed with up to more than a dozen lesions of 
basal cell carcinoma, multiple actinic keratosis lesions, 
as well as Bowen’s disease or melanomas. Therefore, 
a thorough history and physical examination are ex-
tremely important. Considering the proven usability 
of dermatoscopy in early skin-tumour diagnostics, it is 
recommended to deem such a simple and non-invasive 
diagnostic method as a permanent element of the physi-
cal examination [7–9]. It is extremely important to per-
form the dermatoscopy in atypical cases, requiring the 
exclusion of lesions with different aetiology (differential 
diagnostics) to assess small lesions and to differentiate 
actinic keratosis lesions from pre-invasive SCC (in situ). 
The examination should also be used to assess the lesion 
dimensions prior to the treatment, to assess how radical 
the treatment should be, and to monitor the patient’s 
condition following the treatment.
Another non-invasive diagnostic procedure, confocal 
laser scanning microscopy, due to its limited availability 
is still used mainly for research.
In ambiguous cases or to select the appropriate 
therapeutic model, histopathological examination of 
the skin lesion sample remains the “gold standard”. 
The histopathological type of the tumour as well as its 
severity with the assessment of the patient’s condition 
are crucial for the following decisions to be made.
A suspected invasive lesion (with the following signs 
and symptoms: deep infiltration, involvement of the 
tissues and structures below/surrounding the tumour 
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Table 1. Skin cancer risk factors [6]
Skin cancer risk factors SCC BCC
Environmental factors Cumulative UV dose
Intensive interrupted sunbathing
Ionising radiation
Exposure to chemicals*
HPV Infections
×
×
×
×
×
×
(×)
Genetic factors Nicotinism
Skin phenotype 1
Papery and pigment skin
“Eye and skin” albinism
Epidermodysplasia verruciformis 
Epidermolysis bullosa
Ferguson-Smith syndrome
Muir-Torre syndrome
Bazex syndrome 
Rombo syndrome
Gorlin-Goltz syndrome
×
×
×
×
×
×
×
×
×
×
(×)
(×)
×
×
×
Chronic skin 
conditions
Chronic non-healing skin ulcerations 
Persisting:
— skin lupus erythematosus
— lichen planus (erosivus)
— lichen sclerosis
Porokeratosis 
Nevus sebaceus
×
×
×
×
Immunosuppression Status-post organ transplantation
Other types of immunosuppression, e.g. AIDS, HPV infection
×
×
(×)
*Chemicals: arsenic, mineral oil, coal tar, soot, nitric yperite, aromatic polycyclic compounds — biphenyl derivatives, 4,4’bipyridyl, psoralen (including UVA) 
[1, 2, 4–6]
— i.e. muscles, bones, nerves, lymph nodes, eyeball) 
constitutes an indication to extend diagnostics with 
imaging (CT, MRI) [1, 4, 5, 7, 10–12]. If the physical 
examination or imaging show enlarged regional lymph 
nodes, fine-needle biopsy should be performed or the 
whole lymph node should be sampled for histopathologi-
cal examination [1, 4].
The next stage consists of the assessment of prognos-
tic factors for individual neoplastic lesions, allocating the 
tumours to high- or low-risk group (Table 2 and 3) and in 
the severity assessment according to the American Joint 
Committee on Cancer (AJCC) revision 2009 (Table 4).
In a prospective study lasting 20 years (average pe-
riod 43 months) on 615 patients, Brantsch et al. proved 
a correlation between the infiltration depth of the SCC 
and frequency of local recurrence/spread. If the infiltra-
tion depth did not exceed 2 mm, the recurrence rate was 
0%. If the infiltration depth was 2.1 mm up to 6 mm 
— the recurrence rate was 4%, while in the case of the 
infiltration depth exceeding 6 mm — it was 16%. The 
tumour’s invasive severity was also correlated with the 
Clark scale infiltration depth. The factors listed above 
are significant for the prognosis.
Diagnostic and therapeutic 
recommendations
Radical tumour resection constitutes the superior 
treatment objective in skin cancer patients. Therefore, 
more radical methods with the lowest local failure risk 
should be the first choice.
The treatment should be selected based on:
 — clinical assessment, quantity, and dimensions of the 
skin cancer lesions;
 — histopathological type;
 — neoplasm invasiveness, risk of its local and distant re-
currence (risk of distant metastasis or local recurrence);
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Table 2. Risk assessment in the case of squamous cell carcinoma [1, 3, 4]
Risk factors for local and distant recurrence of SCC
Location and dimensions Low-risk lesion High-risk lesion
Edges
Region L< 20 mm 
Region M < 10 mm 
Region H < 6 mm
Sharp, well defined
Region L ≥ 20 mm
Region M ≥ 10 mm
Region H ≥ 6 mm
Ill-defined edges
Primary/recurrent tumour Primary Recurrent
Immunosuppression No Yes
Previous radiotherapy or chronic 
inflammation within the tumour
No Yes
Rapid growth of the tumour No Yes
Neurological signs and symptoms No Yes
Histological differentiation Well or moderately differentiated G1, G2 Poorly differentiated G3
Tumour thickness < 2 mm ≥ 2 mm
Nerve and vessel infiltration
Clark level I–III
No
Clark level IV–V
Yes
Histopathological type — metatypicus
— verrucosus
— fusiformis
— mixtus
— acantholiticus
— desmoplasticus
— adenoidalis, adenoidosquamousus
— mucosoadenoidalis
— fusiformis (post-radiotherapy)
Region L: torso and extremities, excluding anterior crus, hands, feet, ankles, and nails
Region M: middle area of the face, cheeks, forehead, haired skin on the head, neck, and anterior crus
Region H: head and neck excluding region M, genital area, hands, and feet
Table 3. Risk assessment for basal cell carcinoma [1, 3, 4]
BCC recurrence risk factors
Location and dimensions Low-risk lesion High-risk lesion
Edges
Region L< 20 mm 
Region M < 10 mm
Region H < 6 mm
Sharp, well-defined
Region L ≥ 20 mm
Region M ≥ 10 mm
Region H ≥ 6 mm
Ill-defined edges
Primary/recurrent tumour Primary Recurrent
Immunosuppression No Yes
Previous radiotherapy No Yes
Histopathological type — superficial
— follicular
— fibroepithelioma
— keratising
— folliculocystic
— cicatricial
— sclerodermal
— metatypic
— infiltrating
— nodular lesions in any tumour region
Nerve infiltration No Yes
Region L: torso and extremities, excluding anterior crus, hands, feet, ankles and nails
Region M: middle area of the face, cheeks, forehead, haired skin on the head, neck, anterior crus
Region H: head and neck excluding region M, genital area, hands and feet
250
OncOlOgy in clinical practice 2015, Vol. 11, No. 5
www.opk.viamedica.pl
Table 4. Skin cancer advancement (2009)
T (pRImaRy LESIon)*
Tx No assessment possibility
T0 No signs of primary lesion
Tis Cancer in situ
T1 Tumour with the maximum dimensions of ≤ 2 cm and < 2 high risk factors#
T2 Tumour with the maximum dimensions of > 2 cm or a tumour with any dimensions with ≥ 2 high risk factors#
T3 Tumour with jaw, mandibular, orbital cavity, or temporal bone infiltration
T4 Tumour with spine infiltration or nerve infiltration into the skull base
*Shall not apply to the clinical picture of the squamous cell carcinoma of an eyelid; #high-risk factors for the primary lesion (T)
High risk factors
Depth of the primary lesion infiltration > 2 mm
Clark infiltration level ≥ IV Nerve area infiltrations
Lesion locations Auricle
Vermilion zone
Vermilion border
Differentiation Poorly or non-differentiated
n (REGIonaL LympH nodES)
nx No assessment possibility
n0 No metastases to lymph nodes
n1 Metastasis to a single lymph node, within the confluence on the side of the primary lesion, lymph node 
dimensions ≤ 3 cm in its largest dimension
n2 Metastasis to a single lymph node within the confluence on the side of the primary lesion, lymph node 
dimensions > 3 cm and < 6 cm; alternatively, metastases to multiple lymph nodes on the side of the primary lesion 
with no lymph node exceeding 6 cm; alternatively, bilateral metastases or metastases to the side opposite to the 
primary lesion, with the lymph node dimensions < 6 cm
n2a Metastasis to a single lymph node within the confluence on the side of the primary lesion, lymph node 
dimensions > 3 cm and < 6 cm
n2b Metastases to multiple lymph nodes on the side of the primary lesion with no lymph node exceeding 6 cm
n2c Bilateral metastases or metastases to the side opposite to the primary lesion with the lymph nodes not exceeding 6 cm
n3 Metastasis to a lymph node with the dimensions > 6 cm in its largest dimension
m (dISTanT mETaSTaSIS)
m0 No metastases
m1 Metastases
SEVERITy LEVELS oF a maLIGnanCy
Level 0 Tis N0 M0
Level 1 T1 N0 M0
Level 2 T2 N0 M0
Level 3 T3
T1
T2
T3
N0
N1
N1
N1
M0
M0
M0
M0
Level 4 T1
T2
T3
T each
T4
T each
N2
N2
N2
N3
N each
N each
M0
M0
M0
M0
M0
M1
HISTopaTHoLoGICaL TUmoUR maLIGnanCy GRadES (G)
Gx Assessment is impossible
G1 Well differentiated
G2 Moderately differentiated
G3 Poorly differentiated
G4 Non-differentiated
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Figure 1. Recommended diagnostic and therapeutic actions recommended in the case of suspected skin cancer
 — maintenance of the organ/body part functions and 
the final effects of the treated area;
 — therapy effectiveness assessed as the percentage of 
recurrence within 4–6 months and 3–5 years (veri-
fied with physical examination, dermatoscopy, and 
histopathological examination);
 — treatment tolerance (pain, treatment period, adverse 
reactions, risk of complications);
 — availability of a given therapeutic method;
 — patient’s immune competence;
 — individual preferences of the patient.
Surgery often constitutes the fastest and the most 
effective method of curing the condition; however, 
the doctor deciding on the strategy of treatment 
should consider mainly: the patient’s (old) age and 
multiple internal conditions, and psychological and 
aesthetic issues. Therefore, in some cases other 
methods of treatment, alternative to surgery, are 
acceptable (mainly in the case of cancers with low 
recurrence risk).
It should be underlined that high-quality compara-
tive research of various skin cancer treatment methods is 
yet to be done. Most publications refer to the lesions with 
a low recurrence risk/invasiveness. Surgical treatment 
of skin cancer (except for inoperable lesions) remains 
the “gold standard” [1, 4, 5, 7].
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Skin cancer treatment — basic 
treatment
Resection with histopathological assessment  
of surgical margin
This is the most common skin cancer treatment 
method (for both low and high recurrence-risk cancers). 
A surgical margin of no less than 4 mm is recommended 
for BCC and a margin of 6 mm for SCC. In the case 
of high-risk cancers, intraoperative radicality control 
(Mohs micrographic surgery) is recommended. If this is 
not possible, wider resection margins are recommended 
— 10 mm. If such extended margins of unaffected skin to 
be resected affect the aesthetics, radical resection with 
lower margins may be considered (R0 margins — the 
histopathological examination showed no neoplastic 
cells within the margin) — the margin required under 
the Mohs micrographic surgery. Mohs micrographic 
surgery consists of tumour resection in layers with 
intraoperative assessment of the frozen section of the 
tumour bed edges and bottom. Individual sections are 
carefully marked so that, following the results obtained, 
only the margins are extended, where neoplastic cells 
were found. Such a procedure allows for radical tumour 
resection saving the healthy tissues to the greatest extent 
possible [1, 4, 5, 7, 10].
Radiotherapy
Independent radiotherapy may be applied for both 
BCC and SCC (with both low and high recurrence risk) 
in patients over the age of 60 years as an alternative to 
primary tumour resection. This method is particularly 
applicable in Bowen’s disease patients, in the case of 
large tumour or with multiple focal lesions, or when the 
patient refuses to agree to the resection.
Augmentation radiotherapy is used in the case of lo-
cally and regionally advanced skin cancers (in particular 
in the case of nerve infiltration diagnosed), following 
lymphadenectomy due to SCC metastases to the re-
gional lymph nodes, as well as when the surgery was not 
radical and surgical radicalisation is not possible. The 
method is also recommended in the case of skin tumour 
resection with Mohs micrographic surgery.
The disadvantages of radiotherapy include early 
stage and delayed complications that tend to increase in 
severity in time. They comprise mainly: dermal necrosis, 
radiation dermatitis of the mucosa, and pigmentation 
(permanent skin discolorations).
Radiotherapy contraindications include:
 — genetic factors predisposing basal cell carcino-
ma conditions;
 — xeroderma pigmentosum;
 — age below 60 years (relative contraindication);
 — cicatricial basal cell carcinoma;
 — lesions in the following areas: auricle, hands, feet, 
extremities, and genital area.
Chemotherapy
There are no data available on spreading SCC pa-
tients, which would unambiguously confirm the cisplatin 
monotherapy or a chemotherapy with cisplatin com-
bined with 5-fluorouracil, interferon, cis-retinoic acid. 
There are communications on the possible effectiveness 
of the EGFR inhibitors (cetuximab, gefitinib) available; 
however, additional clinical studies are required in that 
respect [1, 4–7, 10, 11, 13].
Hedgehog pathway inhibitors
In patients genetically predisposed to multiple 
BCCs (Gorlin and Goltz syndrome), in patients suf-
fering from spreading BCC, as well as in patients 
with regionally advanced BCC, who exhausted the 
possibilities under surgical and radiological therapies, 
therapy with vismodegib is possible (microparticle 
Hedgehog pathway inhibitor). The medicine (in the 
dose of 150 mg/d) prolonged the condition’s progress 
with an objective response rate of 30% to 60%. The 
most common adverse events reported during the 
vismodegib therapy (in > 30% of patients) include 
muscle spasms, balding, taste disorders, weight loss, 
fatigue, and nausea [14–16]. Another Hedgehog path-
way inhibitor already registered in the United States 
is sonidegib [14–17].
Clinical studies
For regional or systemic BCC or SCC patients who 
exhausted their therapeutic possibilities, inclusion into 
the clinical studies should be considered [1, 4, 14, 15, 
17, 18].
Skin cancer treatment with irradiation and/or chem-
otherapy and targeted treatment should be conducted 
in high profile centres.
Skin cancer treatment — superficial 
methods
In the case of low recurrence risk BCC and SCC, 
superficial methods may be considered. Due to their 
poorer effectiveness, they should be limited to those 
patients for whom the basic (mainly surgical) treatment 
methods are contraindicated. The superficial treatment 
may also be considered in patients with superficial low 
recurrence risk basal cell carcinoma, if the expected 
aesthetic effect is more acceptable.
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5-fluorouracil
This medicine is used in the treatment of actinic 
keratosis, superficially spreading basal cell carcinoma, 
and squamous cell carcinoma in situ. The medicine is 
administered twice daily for 4, 6, or 11 weeks in the case 
of superficial BCC (comprehensive response is obtained 
in 90% of patients). In the case of the actinic keratosis, 
the medicine is administered for 2–4 weeks on average 
(comprehensive response in 82% of skin lesions) [1, 
4–7, 10, 11, 19].
Imiquimod (5%)
This medicine is used in the treatment of the actinic 
keratosis, SCC in situ/Bowen’s disease, and non-invasive 
superficially spreading BCC. The cream is applied for 
a longer period (studies have shown that treatment 
prolongation from 6 to 12 weeks is more effective) and 
more often (once or twice daily), resulting in decreased 
risk of ineffective treatment. Its application in occlu-
sion for the superficial and nodular form of BCC with 
diameter up to 2 cm is similarly effective. For example, 
in 84% of superficial BCC patients, the symptoms did 
not recur for five years. In the case of immune competent 
patients only the cream is applicable, while in the case 
of patients taking immunosuppressants, the treatment 
with imiquimod should be combined with cryosurgery, 
Mohs microsurgery, or photodynamic method [1, 4–7, 
10, 11, 19].
Photodynamic method
In the case of skin cancers, the method is recom-
mended for the treatment of superficially spreading 
and nodular BCC as well as SCC in situ/ Bowen’s dis-
ease and actinic keratosis. Aminolevulinic acid (ALA) 
and methyl aminolevulinate (MAL) are used with that 
method. Lamps or lasers may constitute the light source. 
A randomised multi-centre study assessed the treatment 
effectiveness of 601 lesions of the superficially spread-
ing BCC. The cancer remitted in 72.8% of patients 
treated with MAL-PDT (two cycles with a week’s break) 
compared to 83.4% of patients treated with imiquimod 
(five times a week for six weeks) and 80.1% of patients 
treated with 5-fluorouracil (twice daily for fourweeks) 
[1, 4, 20, 21].
Other studies have shown the effectiveness of the 
photodynamic method (defined as the comprehen-
sive response percentage after three months and two 
years) in the treatment of actinic keratosis (93% and 
69%, respectively), Bowen’s disease (93% and 68%, 
respectively), as well as superficial BCC (93% and 85%, 
respectively) and nodular BCC (75–82% and 77%, re-
spectively, after 60 months) [20, 21].
The consensus on the treatment of the BCC patients 
suffering from Gorlin and Goltz syndrome with the pho-
todynamic method was published in 2013. Based on the 
analysis of nine reviews summarising the results of 83 pa-
tients, the photodynamic method was deemed to be safe 
and effective in the treatment of superficially spreading 
and nodular BCC with the infiltration depth not exceed-
ing 2 mm. The authors of the consensus recommended 
determining the frequency of the follow-up appointments 
depending on the number of BCC lesions, recurrence 
frequency, and location of the lesions. The possibility of 
treating many lesions simultaneously was underlined as 
a significant advantage of the photodynamic method [22].
The effectiveness of assessment of the topical treat-
ments of Bowen’s disease was published in 2013, based on 
the analysis of randomised controlled studies estimating the 
treatment effectiveness following 12 months of treatment. 
A lack of high quality studies was indicated. The publica-
tions available allowed for provision of higher effectiveness 
of the MAL-PDT treatment compared to cryotherapy as 
well as similar effectiveness compared to 5-FU and similar 
effectiveness of 5-FU and cryotherapy [11, 20].
On the other hand, the meta-analysis of the actinic 
keratosis treatment effectiveness on the face and/or 
head with MAL-PDT compared to other procedures 
was published in 2014. After three months following 
the therapy completion, the PDT effectiveness was 14% 
higher compared to cryotherapy [23].
A systematic review of studies assessing the topical 
treatment of the actinic keratosis lesions following three 
months and two years published in 2012 showed the ef-
fectiveness of all the methods under analysis, with the 
best aesthetic effects obtained with PDT and imiquimod 
[20]. The photodynamic method was recommended for 
small areas because it proved to be more effective than 
cryotherapy. On the other hand, topical treatment (im-
iquimod, 5FU, 3% diclofenac, ingenol mebutate) was 
recommended for large skin areas because they were 
proven to be similarly effective [13, 18, 23].
Cryotherapy
Cryotherapy is a technique leading to neoplastic cell 
necrosis by decreasing the tissue temperature down to –50° 
or even –60°C. It is used in the treatment of superficial 
skin cancers with low recurrence risk and dimensions not 
exceeding 2 cm, as well as actinic keratosis lesions. It is 
not recommended for nodular cancers. The variety of 
the cryotherapies available makes the effectiveness of the 
method presented in various studies incomparable [1, 4, 7].
Remarks
Due to the lack of reliable scientific evidence based 
on randomised clinical studies showing the effective-
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ness of skin cancer treatment with curettage or electric 
destruction, unlike the recommendations of the EU and 
NCCN, the Oncology Department of the PTD as well 
as the Melanoma Academy Department of the PTChO 
do not recommend those methods.
For the same reasons, the Oncology Department 
of the PTD as well as the Melanoma Academy Depart-
ment of the PTChO does not recommend any other 
methods of neoplastic tissue destruction with laser 
therapy, dermabrasion, and chemical peeling (with 
trichloroacetic acid), rendering the treatment radicality 
control impossible.
Several randomised studies assessing the effective-
ness of intralesional interferon injections in the treatment 
of BCC, despite moderate effectiveness in the treatment 
of small superficial and nodular BCCs, were bound to 
a high percentage (approximately 30%) of early stage 
failures and frequent adverse reactions. Therefore, 
the Oncology Department of the PTD as well as the 
Melanoma Academy Department of the PTChO do not 
recommend that therapeutic method [1, 2, 4–7, 10, 11].
Monitoring following completed 
oncological treatment
The requirement of strict monitoring of skin cancer 
patients is mostly due to the following reasons:
 — 30–50% of skin cancer patients will develop a lesion 
of a similar cancer within the next five years;
 — 70–80% of SCC recurrences occur within the first 
two years of monitoring;
 — skin cancer patients are 10-times more likely to 
develop a skin cancer again compared to the gen-
eral public;
 — the risk of developing melanoma is higher in skin 
cancer patients;
 — high risk of invasive forms of SCC is typical for 
patients undergoing chronic immunosuppression.
Any suspected recurrence of skin cancer should be 
confirmed with histopathological examination. Derma-
toscopic examination often allows precise determination 
of the biopsy site and diagnosis of a recurrence at an 
early stage [10, 11].
If enlarged lymph nodes are found, a fine-needle 
biopsy (more seldom the whole lymph node should be 
taken for histopathological examination) and imaging 
(CT, MRI) should be performed to assess the severity 
of the condition [1, 4, 5, 7].
Rules of monitoring following the treatment
A. BCC or SCC:
 — photoprotection with SPF 30–50+ throughout 
the year;
 — self-control by the patient once a month;
 — dermatological and dermatoscopic examinations of 
the whole body every 4–6 months for 5 years, and 
every 6–12 month for the rest of the patient’s life.
B. Regionally advanced/spreading BCC or SCC: 
 — photoprotection with SPF 30–50+ throughout 
the year;
 — self-control by the patient once a month;
 — dermatological and dermatoscopic examinations 
of the whole body: every 1–3 months for the first 
year, every 2–4 months during the second year, 
every 4–6 months during the third year, and every 
6–12 months for the rest of the patient’s life;
 — multidisciplinary care (mainly of: a dermatologist, 
an oncologist, a radiotherapist, a neurologist, and 
an ophthalmologist).
Monitoring patients after organ transplantation during 
chronic immunosuppression:
 — photoprotection with SPF 30–50+ throughout 
the year;
 — self-control by the patient once a month;
 — dermatological and dermatoscopic examinations of 
the whole body: every 6–12 months for the rest of 
the patient’s life;
 — in the case of a skin cancer, the control is recom-
mended every 3–6 months for the rest of the pa-
tient’s life.
Monitoring patients genetically predisposed to develop 
skin cancer:
 — photoprotection with SPF 30–50+ throughout 
the year;
 — self-control by the patient once a month;
 — dermatological and dermatoscopic examinations 
of the whole body: every 3–6 months for the rest of 
the patient’s life;
 — in xeroderma pigmentosum patients — considering 
reversal of the daily schedule and absolutely avoid-
ing UV, IR, and X-ray radiation exposure at work.
Skin cancer prevention
Primary prevention:
 — strict dermatological monitoring of patients ge-
netically predisposed to developing UV-induced 
skin cancer and patients undergoing a chronic im-
munosuppression;
 — educating society about correct photoprotection and 
the possibilities of early diagnostics of skin cancers 
[22, 24].
Secondary prevention:
 — educating patients about correct photoprotection;
 — educating patients about the skin cancer signs 
and symptoms as well as the requirement to 
self-control;
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 — regular monitoring appointments with a dermatolo-
gist and with dermatoscopy according to the schedule 
[8, 9, 24];
 — in the case of the patients undergoing chronic im-
munosuppression with the signs of actinic keratosis 
and/or NMSC, considering the treatment modifi-
cation with reduction of the doses of calcineurin 
inhibitors and/or antimetabolites for the benefit of 
mTORs [23].
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